SelSym Biotech

This is going to be a super-impactful event for everyone in the RTP biotech ecosystem. The agenda is packed with remarkable speakers sharing their insights and experiences in the Business of Innovation. Hope to see lots of folks there on September 25th - and definitely make sure you are there to hear from our CEO, Seema Nandi, Ph.D. who will be sharing some "tales from the trenches"!

The technology behind SymClot was recently featured by NHLBI, with a focus on work funded by an STTR. This work has the potential to completely change how we manage traumatic bleeding in the field, and in hospital/clinic-based emergency and surgical settings. Not only does the product act as an "artificial platelet", thereby providing an avenue to replacing hard-to-store and difficult-to-transport platelet-based products, it also has the potential to be the first line of treatment for bleeding even in cases where platelets wouldn't be normally used. We are focused on transforming the standards of care in bleeding management and wound healing, and SymClot is poised to become the the lead product in that mission. https://lnkd.in/g3fSFcCC

Thanks to UVA Engineering for featuring the latest work on the team’s hemostasis technology. Excellent write up that really captures the clinical potential of platelet-like particles. https://lnkd.in/gCaKGW_G

SelSym is hiring! Check out this new opportunity to join our R&D team: https://lnkd.in/g7YKeHYe

Another excellent writeup on platelet-like particles - thanks to the National Science Foundation (NSF) for featuring this work! Joint Department of Biomedical Engineering | UNC & NC State Chapman Fowler School of Engineering University of Virginia Department of Biomedical Engineering https://lnkd.in/gazFgjAm

Thanks to Emily Mullin over at WIRED for this outstanding article on the Platelet-Like Particle technology. Lots of great stuff from some thought leaders in the worlds of hematology and trauma discussing the challenges and opportunities for platelet mimetics. SymClot has been designed to address those very challenges, and all of us here at SelSym are tremendously optimistic for the future of this work! Joint Department of Biomedical Engineering | UNC & NC State NCSU College of Veterinary Medicine University of Virginia Department of Biomedical Engineering Chapman University Chapman Fowler School of Engineering Chapman University Schmid College of Science and Technology Duke University School of Medicine https://lnkd.in/dX5gr5kb

Another nice writeup on the technology that underpins SymClot - this time highlighting the west coast connections at Chapman Fowler School of Engineering and Chapman University Schmid College of Science and Technology. Thanks for being part of the team that brought this research to fruition Andrew Lyon and Sanika Pandit! Note: Sanika has now traded coasts to ply her trade at the Joint Department of Biomedical Engineering | UNC & NC State. 😁 https://lnkd.in/gD-7bek3

Thanks to Sharon Reynolds over at The National Institutes of Health #ResearchMatters for writing up the latest work on #PlateletLikeParticles, where she featured commentary from the study's lead author (and SelSym Biotech co-founder) Ashley Brown. This is a really nice article that showcases some of the truly transformational aspects of this NIH-funded research! Joint Department of Biomedical Engineering | UNC & NC State https://lnkd.in/g9d8crkV

We chatted with The Naked Scientists...and it was pretty cool. Recently, SelSym co-founder Ashley Brown had the opportunity to sit down to talk about her recent advances in artificial platelet technologies. That work is a foundational piece of SelSym's SymClot product, and clearly points the way forward to clinical translation of the innovation. Joint Department of Biomedical Engineering | UNC & NC State https://lnkd.in/gvpbSvC3

In case you missed it, SelSym Biotech is in the news! https://lnkd.in/gspH8Tae SelSym's co-founder (and founding CEO) Ashley Brown led a multi-university, multi-investigator team that included her fellow co-founders, Seema Nandi, Ph.D. (current CEO), Andrew Lyon (CSO), and Tom Barker (President), our Director of Translational Clinical Development, Kimberly Nellenbach, PhD., and one of our trusted clinical advisors Maureane Hoffman on a major project that clearly shows the efficacy and safety of platelet-like particles in a range of animal models. Furthermore, this work illustrates the ability of these particles to clear from circulation via renal excretion, which makes the innovation potentially transformative in the world of injectable bio-nanomaterials. For more information on this remarkable advancement, check out the original article in Science Translational Medicine: https://lnkd.in/gX9TRmt7 #hemostasis #trauma #regenerativemedicine #woundhealing #platelets